drug
edaravone
Marketedupdated 3mo agoby $SGIOF SHIONOGI & CO LTD
Approvedcommunity read0 votes
Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for axial length measurement and amyotrophic lateral sclerosis and 6 investigational indications.
indications
investigational
ALS
all catalysts(0)
nothing on the calendar yet
Trials studying edaravone
- phase2Safety and Efficacy of Edaravone Dexborneol Sublingual Tablets for Blood-Brain Barrier Dysfunction in CADASIL
- phase1Bioequivalence of TTYP01 Tablets in Healthy Adult Subjects
- phase4Edaravone-Sodium Ozagrel Comparative Post-Marketing Study on Acute Ischemic Stroke
- phase2Study of Compound Edaravone Injection for Treatment of Acute Ischemic Stroke
- —Radicava® (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS)
- phase3Effect of Early Versus Late Initiation of Edaravone Dexborneol on Neural Function in Patients With Acute Ischemic Stroke
Patent cliff
source: FDA Orange Bookfirst barrier falls
May 12, 2029
~2.8 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (11)
- Nov 12, 2041method-of-use (U-4111)US 12194025
- Nov 12, 2041method-of-use (U-4111)US 12310946
- Nov 12, 2041method-of-use (U-4111)US 12478611
- Nov 12, 2041method-of-use (U-4111)US 12527769
- Nov 12, 2041method-of-use (U-4111)US 12569469
- Nov 1, 2039formulationUS 10987341
- Nov 1, 2039formulationUS 11241416
- Nov 1, 2039method-of-use (U-3468)US 11478450
- Nov 1, 2039formulationUS 11826352
- Nov 1, 2039formulationUS 11957660
- Nov 1, 2039formulationUS 12285409
FDA exclusivities (1)
- May 12, 2029ODE-144Orphan Drug (7y)2.8y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 9m ago
Found something off?
comments(0)
5-min edit window · permanent after that